The purpose of this study is to compare the usual treatment alone (immune based therapy with medications like durvalumab) to the usual treatment plus the study medication AZD6738 (ceralasertib) in patients with lung cancer who have completed surgery following chemotherapy and immunotherapy.
Learn more about the EA5231/CLEAR trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
